文献速递妇科

基于宫颈阴道液蛋白质组学的新型卵巢癌筛查方法:窥视腹腔的窗口

A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
PubMed 文献 · Gynecol Oncol · 2021-10-30

本研究前瞻性收集83例连续患者样本(33例卵巢癌、50例对照),用液相色谱-质谱蛋白质组学评估宫颈阴道液,统计建模确定5种蛋白组成的指纹面板,ROC曲线AUC为0.86(p=0.00001),医生采集与患者自采集样本一致性中等(kappa平均0.6,上限0.75)。

要点

  • 宫颈阴道液蛋白质组学可构建卵巢癌检测指纹,AUC为0.86(p=0.00001)。
  • 5种蛋白指纹面板包括丝氨酸蛋白酶抑制剂A1、周斑蛋白、前纤维蛋白1、载脂蛋白A1和胸腺素β4样蛋白。
  • 医生采集与患者自采集样本一致性中等,kappa平均0.6(上限0.75)。

核心结论

  • 使用新型部位特异性采集方法,识别出具有足够敏感性和特异性的卵巢癌指纹,值得在更大队列中进一步评估。
  • 医生采集与患者自采集样本的一致性令人鼓舞,若该筛查试验在未来研究中得到验证,家庭自采集可改善筛查可及性。

研究设计与样本

  • 前瞻性连续收集83例患者样本(33例卵巢癌、50例对照),采用液相色谱-质谱蛋白质组学评估宫颈阴道液。
  • 统计建模确定在卵巢癌样本中穿透率最高的蛋白面板。
  • 30例患者同意在家自采集阴道样本并填写可行性问卷。
  • 采用Cohen kappa方法确定医生采集与患者自采集样本的一致性。

主要发现

  • 30种肽段在检测卵巢癌中显示独立统计学显著性。
  • 统计建模确定的最佳预测蛋白面板形成由5种蛋白组成的指纹:丝氨酸蛋白酶抑制剂A1、周斑蛋白、前纤维蛋白1、载脂蛋白A1和胸腺素β4样蛋白。
  • 这些肽段检测卵巢癌的概率显著增加,ROC曲线AUC为0.86(p=0.00001)。
  • 医生采集与患者自采集样本显示中等一致性,kappa平均0.6,上限0.75。

关键数值与推荐

  • 卵巢癌检测蛋白指纹面板由5种蛋白组成:丝氨酸蛋白酶抑制剂A1、周斑蛋白、前纤维蛋白1、载脂蛋白A1和胸腺素β4样蛋白。
  • ROC曲线AUC为0.86(p=0.00001)。
  • 医生采集与患者自采集样本一致性kappa平均0.6,上限0.75。

临床怎么用

  • 作者认为该卵巢癌指纹具有足够敏感性和特异性,值得在更大队列中进一步评估。
  • 作者认为若该筛查试验在未来研究中得到验证,家庭自采集可改善筛查可及性。

局限性

  • 原文结论指出需在更大队列中进一步评估。
  • 原文结论指出该筛查试验需在未来研究中得到验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective is to develop a site-specific proteomic-based screening test for ovarian cancer(OC) using the mucus of the cervix and vagina and evaluate a potential means for home testing. METHODS: Cervicovaginal fluid samples were obtained from ovarian cancer and normal control patients for LC-mass spectrometry(MS) proteomic evaluation. Statistical modeling determined the protein panel with the highest penetrance across ovarian cancer samples. A subcohort of patients consented to provide self-collected vaginal samples at home with questionnaire on feasibility. Cohen's kappa methodology was utilized to determine agreement between physician-collected and patient-collected samples. RESULTS: A total of 83 consecutive patient samples were collected prospectively (33 ovarian cancer & 50 controls). Thirty patients consented for self-collection. Using LC-MS, 30 peptides demonstrated independent statistical significance for detecting ovarian cancer. Using statistical modeling, the protein panel that determined the best predictor for detecting OC formed a "fingerprint" consisting of 5 proteins: serine proteinase inhibitor A1; periplakin; profilin1; apolipoprotein A1; and thymosin beta4-like protein. These peptides demonstrated a significant increase probability of detecting ovarian cancer with the ROC curve having an AUC of 0.86 (p = 0.00001). Physician-collected and patient-collected specimens demonstrated moderate agreement with kappa average of 0.6 with upper bound of 0.75. CONCLUSIONS: Using novel site-specific collection methods, we identified an OC "fingerprint" with adequate sensitivity and specificity to warrant further evaluation in a larger cohort. Agreement of physician-collected and patient-collected samples were encouraging and could improve access to screening with a home self-collection if this screening test is validated in future studies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rocconi RP, Wilhite AM, Schambeau L, et al. A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen. Gynecol Oncol. 2021. PMID: 34756750. doi:10.1016/j.ygyno.2021.10.083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。